Clinical Trial Update: Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics. [Phase 4]

View source ↗

Summary

Phase 4 trial update on bezlotoxumab as secondary prophylaxis for Clostridium difficile in high-risk hospitalized patients exposed to antibiotics; study termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• Bezlotoxumab (bezlotoxumab)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Clostridium Difficile | Phase 4 | Status: TERMINATED | Results posted: 2022-11-09